SCHEMBL1638569

SCHEMBL1638569

O=C(c1ccccc1)c1cccc(-c2ccccc2)c1OCc1ccccc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER1 P34995 6/20 0.50
CCNB2 O95067 1/20 0.49
CCNE2 O96020 1/20 0.49
CDK1 P06493 1/20 0.49
CCNB1 P14635 1/20 0.49
CCNE1 P24864 1/20 0.49
CDK2 P24941 1/20 0.49
CCNB3 Q8WWL7 1/20 0.49
RXRA P19793 1/20 0.49
RXRB P28702 1/20 0.49
RXRG P48443 1/20 0.49
ALDH1A1 P00352 3/20 0.49
SRD5A2 P31213 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
NR4A2 P43354 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
CYP2C9 P11712 2/20 0.44
MRGPRX4 Q96LA9 1/20 0.44
GAA P10253 1/20 0.44
MAPT P10636 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8797209 0.87 PTGER1 (0.55) PTGER1RXRARXRBRXRGALDH1A1
SCHEMBL1642763 0.86 NR1H4 (0.52) PTGER1RXRARXRBRXRGALDH1A1
SCHEMBL1667777 0.84 BCAT2 (0.56) PTGER1RXRARXRBRXRGHTT
SCHEMBL1639034 0.84 MAOB (0.50) PTGER1RXRARXRBRXRGALDH1A1
SCHEMBL1638633 0.84 CCNB2 (0.51) PTGER1CCNB2CCNE2CDK1CCNB1
SCHEMBL25431505 0.83 ALDH1A1 (0.56) PTGER1RXRARXRBRXRGALDH1A1
SCHEMBL12726013 0.83 SCN9A (0.52) PTGER1RXRARXRBRXRGL3MBTL1
SCHEMBL12725979 0.83 ADORA3 (0.50) PTGER1RXRARXRBRXRGALDH1A1
SCHEMBL8409192 0.82 LMNA (0.55) PTGER1RXRARXRBRXRGALDH1A1
SCHEMBL27894245 0.82 PTGER1 (0.47) PTGER1RXRARXRBRXRGALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8557936-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-10-15 US disclosed
US-8557936-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-10-15 US disclosed
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
US-8541522-B2 Catalyst compounds and use thereof EXXONMOBIL CHEMICAL PATENTS INC. (US) 2013-09-24 US disclosed
EP-2493934-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
EP-2493932-A2 CATALYST COMPOUNDS AND USE THEREOF ExxonMobil Chemical Patents Inc. (US) 2012-09-05 EP disclosed
WO-2011056428-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
WO-2011056423-A2 CATALYST COMPOUNDS AND USE THEREOF EXXONMOBIL CHEMICAL PATENTS INC. (US) 2011-05-12 WO disclosed
US-20110098425-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098425-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed
US-20110098429-A1 Catalyst Compounds and Use Thereof EXXONMOBIL CHEMICAL PATENTS INC. 2011-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110098425-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 PTGER1 2069/4885CCNB2 1991/4885CCNE2 2314/4885
US-20110098429-A1 Catalyst Compounds and Use Thereof ALOX12, THEM6, ALOX15 PTGER1 2069/4885CCNB2 1991/4885CCNE2 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.